Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of the American College of Surgeons

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JAMCOLLSURG.2005.01.024PMID 15922194
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases

  2004cited by this paper
• Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy

  2003cited by this paper
• 1088 Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: results of EORTC GI group study 40986

  2003cited by this paper
• Impact of steatosis on perioperative outcome following hepatic resection

  2003cited by this paper
• Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases

  2003cited by this paper
• Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.

  2002cited by this paper
• Oxaliplatin: results in colorectal carcinoma.

  2002cited by this paper
• The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.

  2002cited by this paper
• Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.

  2002cited by this paper
• The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis

  2001cited by this paper
• Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

  2001cited by this paper
• Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.

  2001cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy

  2000cited by this paper
• Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization.

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

  1999cited by this paper
• Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

  1999cited by this paper
• Long-Term Consequences After Jejunoileal Bypass for Morbid Obesity

  1998cited by this paper
• Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

  1998cited by this paper
• Hepatic steatosis as a potential risk factor for major hepatic resection

  1998cited by this paper
• Steatohepatitis, Spontaneous Peroxisome Proliferation and Liver Tumors in Mice Lacking Peroxisomal Fatty Acyl-CoA Oxidase

  1998cited by this paper
• Hepatic steatosis: Innocent bystander or guilty party?

  1998cited by this paper
• Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy.

  1996cited by this paper
• Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors.

  1995cited by this paper
• Risk factors before hepatectomy, hepatic function after hepatectomy and computed tomographic changes as indicators of mortality from hepatic failure.

  1989cited by this paper
• Severe hepatocellular reaction resembling alcoholic hepatitis with cirrhosis after massive small bowel resection and prolonged total parenteral nutrition.

  1980cited by this paper

• Frequency of Chronic Liver Disease Due to Chemotherapy-Associated Liver Injury in Patients with Gastrointestinal Cancers

  2025cites this paper
• Surgical Management of Colorectal Cancer Liver Metastases.

  2025cites this paper
• Selective portal vein occlusion with hepatic artery preservation reduces posthepatectomy liver failure: a retrospective cohort study

  2025cites this paper
• Impact of neoadjuvant chemotherapy on short-term outcomes after simple and complex minimally invasive minor hepatectomy for colorectal liver metastases: A propensity-score matched and coarsened exact matched study.

  2024cites this paper
• The Use of Hepatic Artery Infusion Chemotherapy for Unresectable Colorectal Cancer Liver Metastases.

  2024cites this paper
• An evaluation model of hepatic steatosis based on CT value and serum uric acid/HDL cholesterol ratio can predict intrahepatic recurrence of colorectal cancer liver metastasis

  2024cites this paper
• Molecular profiling and patient selection for the multimodal approaches for patients with resectable colorectal liver metastases

  2023cites this paper
• Surgical management of liver metastasis from colorectal cancer

  2023cites this paper
• AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

  2023cites this paper
• CACA guidelines for holistic integrative management of rectal cancer

  2023cites this paper
• Protocol for the CoNoR Study: A prospective multi-step study of the potential added benefit of two novel assessment tools in colorectal liver metastases technical resectability decision-making

  2023cites this paper
• Impact of neoadjuvant chemotherapy on post-hepatectomy regeneration for patients with colorectal cancer liver metastasis - Systematic review and meta-analysis.

  2023cites this paper
• Yes, you should do a magnetic resonance imaging (MRI) for patients scheduled for local therapy of colorectal cancer liver metastases: insights into the CAMINO study

  2023cites this paper
• Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (V. 2023)

  2023cites this paper
• The Role of the Multiparametric MRI LiverMultiScanTM in the Quantitative Assessment of the Liver and Its Predicted Clinical Applications in Patients Undergoing Major Hepatic Resection for Colorectal Liver Metastasis

  2023cites this paper
• A resected case of acinar cell carcinoma of the pancreas with liver metastasis following chemotherapy using modified FOLFIRINOX

  2023cites this paper
• Impact of neoadjuvant chemotherapy on the difficulty and outcomes of laparoscopic and robotic major liver resections for colorectal liver metastases: A propensity-score and coarsened exact-matched controlled study.

  2023cites this paper
• Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (2023 edition)

  2023cites this paper
• Extracellular Volume Fraction Calculated Using Contrast-Enhanced Computed Tomography as a Biomarker of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: A Preliminary Histopathological Analysis

  2023cites this paper
• Post-hepatectomy liver failure: A timeline centered review.

  2023cites this paper
• Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

  2023cites this paper
• Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update

  2022cites this paper
• Optimizing the selection of technically unresectable colorectal liver metastases.

  2022cites this paper
• Dietary EPA+DHA Mitigate Hepatic Toxicity and Modify the Oxylipin Profile in an Animal Model of Colorectal Cancer Treated with Chemotherapy

  2022cites this paper
• Right hepatectomy with preservation of the entire caudate lobe in patients with metastatic liver tumors: a case of a new hepatectomy technique and treatment strategy for patients with marginal liver function

  2022cites this paper
• Fat signal fraction assessed with MRI predicts hepatic recurrence following hepatic resection for colorectal liver metastases

  2022cites this paper
• Management of Synchronous Colorectal Cancer Metastases.

  2022cites this paper
• Colorectal Cancer: Management of Distant Metastases

  2021cites this paper
• Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver.

  2021cites this paper
• Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis

  2021cites this paper
• Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature

  2021cites this paper
• Irinotecan-induced NASH and liver failure.

  2021cites this paper
• Surgical Management of Colorectal Cancer Liver Metastases.

  2021cites this paper
• Irinotecan-Induced Steatohepatitis: Current Insights

  2021cites this paper
• Using the win ratio to compare laparoscopic versus open liver resection for colorectal cancer liver metastases

  2021cites this paper
• Short-Term Outcomes of Secondary Liver Surgery for Initially Unresectable Colorectal Liver Metastases Following Modern Induction Systemic Therapy in the Dutch CAIRO5 Trial

  2021cites this paper
• Prognostic impact of neoadjuvant chemotherapy in patients with synchronous colorectal liver metastasis: A propensity score matching comparative study.

  2021cites this paper
• FOLFOX and capecitabine-induced hepatic granuloma mimicking metastasis in a rectal cancer patient

  2020cites this paper
• Steatohepatitis due to FOLFIRINOX regimen in adjuvant pancreas cancer treatment mimicking liver metastasis

  2020cites this paper
• An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management.

  2020cites this paper
• Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study

  2020cites this paper
• A retrospective case-controlled cohort study of inpatient drug induced liver injury: the RIDDLE study.

  2020cites this paper
• Indocyanine green clearance of remnant liver (ICG-Krem) predicts postoperative subclinical hepatic insufficiency after resection of colorectal liver metastasis: theoretical validation for safe expansion of Makuuchi's criteria.

  2020cites this paper
• The effect of preoperative chemotherapy on liver regeneration after portal vein embolization/ligation or liver resection in patients with colorectal liver metastasis: a systematic review protocol

  2020cites this paper
• Fatty liver: The metabolic syndrome increases major hepatectomy mortality.

  2020cites this paper
• ROLE OF 7-CHLORO-4-(PHENYLSELANYL) QUINOLINE IN THE TREATMENT OF OXALIPLATIN-INDUCED HEPATIC TOXICITY IN MICE.

  2020cites this paper
• Minimally invasive liver resections for malignancies: where is the limit?

  2020cites this paper
• Does Chemotherapy-Induced Liver Injury Impair Postoperative Outcomes After Laparoscopic Liver Resection for Colorectal Metastases?

  2020cites this paper
• Other types of diffuse liver disease: is there a way to do it?

  2020cites this paper
• Chemotherapy-associated liver injury in colorectal cancer

  2020cites this paper
• Effect of Chemotherapy on Fatty Liver Occurrence in Breast and Gastrointestinal Cancer Patients: A Case-Controlled Study

  2020cites this paper
• Utility of Image Guidance in the Localization of Disappearing Colorectal Liver Metastases

  2019cites this paper
• Intraoperative liver steatosis characterization using diffuse reflectance spectroscopy.

  2019cites this paper
• Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM)

  2019cites this paper
• Disappearing colorectal liver metastases: Strategies for the management of patients achieving a radiographic complete response after systemic chemotherapy

  2019cites this paper
• The impact of age on post-operative liver function following right hepatectomy: a retrospective, single centre experience.

  2019cites this paper
• Dealing with an insufficient future liver remnant: Portal vein embolization and two‐stage hepatectomy

  2019cites this paper
• CT and MR imaging of chemotherapy-induced hepatopathy

  2019cites this paper
• Multidisciplinary approach of liver metastases from colorectal cancer

  2019cites this paper
• Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False

  2019cites this paper
• Hepatic steatosis in patients undergoing resection of colorectal liver metastases: A target for prehabilitation? A narrative review.

  2019cites this paper
• Focal hypersteatosis: a pseudolesion in patients with liver steatosis.

  2019cites this paper
• Drug-induced liver injury in obesity and nonalcoholic fatty liver disease.

  2019cites this paper
• Modern Management of Hepatic Metastatic Disease

  2019cites this paper
• Prognosis and Management of Recurrent Metastatic Colorectal Cancer

  2019cites this paper
• Systemic Therapy for Colorectal Cancer Liver Metastases: Sorting Through the Options

  2019cites this paper
• Histopathology of Hepatic Sinusoidal Obstruction Syndrome After Neoadjuvant Oxaliplatin-Based Chemotherapy

  2019cites this paper
• Current topics in liver surgery

  2019cites this paper
• Pancreatic Acinar Cell Carcinoma with Multiple Liver Metastases Effectively Treated by S-1 Chemotherapy

  2018cites this paper
• Associating Liver Partition and Portal vein ligation for Staged hepatectomy after pre‐operative chemotherapy

  2018cites this paper
• Future Liver Remnant Indocyanine Green Plasma Clearance Rate as a Predictor of Post-hepatectomy Liver Failure After Portal Vein Embolization

  2018cites this paper
• Pazopanib-Induced Hepatotoxicity in an Experimental Rat Model

  2018cites this paper
• The use of SAMe in chemotherapy-induced liver injury.

  2018cites this paper
• Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.

  2018cites this paper
• Esophagogastric varices were diagnosed in a non-cirrhotic liver case during long-term follow-up after oxaliplatin-based chemotherapy

  2018cites this paper
• Clinical significance of post-hepatectomy hepatic failure in patients with liver metastases from colorectal cancer

  2018cites this paper
• Radiation-Induced Liver Disease and Modern Radiotherapy.

  2018cites this paper
• Surgical Strategy Based on Indocyanine Green Test for Chemotherapy-Associated Liver Injury and Long-Term Outcome in Colorectal Liver Metastases

  2018cites this paper
• Preoperative chemotherapy in the colorectal cancer patients with synchronous metastases to the liver. A vote for YES

  2018cites this paper
• Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy

  2018cites this paper
• Chemotherapy-induced liver injury in metastatic colorectal cancer: about 48 cases

  2018cites this paper
• Post-hepatectomy Liver Failure

  2018cites this paper
• A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer

  2018cites this paper
• Toxicity of Antineoplastic Therapy and Considerations for Perioperative Care

  2017cites this paper
• Hepatic Lesions that Mimic Metastasis on Radiological Imaging during Chemotherapy for Gastrointestinal Malignancy: Recent Updates

  2017cites this paper
• Multidisciplinary Management of Rectal Cancer with Synchronous Resectable Liver Metastases

  2017cites this paper
• Fatty liver and drugs: the two sides of the same coin.

  2017cites this paper
• Mitochondrial adaptation in steatotic mice.

  2017cites this paper
• Conversion Therapy for Initially Borderline/Unresectable Metastases in Colon Cancer: What Is the Best Neoadjuvant Chemotherapy?

  2017cites this paper
• Epidemiology of Hepatic Steatosis at a Tertiary Care Center: An MRI-based Analysis.

  2017cites this paper
• Blood transfusions and steatohepatitis are independent risk factors for complications following liver resection for colorectal cancer liver metastases

  2017cites this paper
• Diagnosis and Treatment of Liver Metastases

  2017cites this paper
• Ursolic acid: A natural preventive aesculapian for environmental hepatic ailments

  2017cites this paper
• SIMULTANEOUS RESECTIONS FOR SYNCHRONOUS COLORECTAL CANCER LIVER METASTASES

  2017cites this paper
• Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers

  2017cites this paper
• Anesthesia in Liver Resections: Review

  2017cites this paper
• Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity

  2017cites this paper
• Metastatic Liver Disease: Associated Liver Lesions

  2017cites this paper
• Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.

  2017cites this paper
• Evolution and revolution of laparoscopic liver resection in Japan

  2017cites this paper